Heart Devices-Focused Edwards Lifesciences Confident in 2025 Outlook, Analyst Sees Long-Term Strength - Edwards Lifesciences ( NYSE:EW )
Q4 sales rose 9% year-over-year to $1.39B, beating the $1.36B consensus. Adjusted EPS of $0.59 topped estimates of $0.55. TMTT sales surged 77% in 2023 to $352M, driven by PASCAL and EVOQUE adoption. TAVR sales reached $1.04B in Q4, up 5.3% year-over-year.
https://www.benzinga.com/general/health-care/25/02/43672055/heart-devices-focused-edwards-lifesciences-confident-in-2025-outlook-analyst-sees-long-term-s